A family of new compounds with sulfonamide and amide functional groups as potential Alzheimer's disease drugs were prepared by multistep synthesis. Thermal stability measurements recorded the initial decomposition in the range of 200-220°C, close above the melting point. The final compounds were tested for their ability to inhibit acetylcholinesterase and butyrylcholinesterase, and the in vitro dissolution behavior of selected compounds was studied through both lipophilic and hydrophilic matrix tablets. All nine tested derivatives were even more active in inhibiting acetylcholinesterase than the clinically used rivastigmine. Regression analysis of the obtained dissolution profiles was performed, and the effects of the pH and the release mechanism were determined. Some substances showed remarkable biological activity and became a subject of interest for further extensive study.

Faculty of Chemical Technology University of Pardubice Pardubice Czech Republic

See more in PubMed

World Health Organization: Neurological disorders affect millions globally: WHO report. (online) Brussels: © 2023 WHO, 2007. (cit. March 16, 2023) https://www.who.int/news/item/27-02-2007-neurological-disorders-affect-millions-globally-who-report

M. Zvěřová, Clin. Biochem. 2019, 72, 3. https://doi.org/10.1016/j.clinbiochem.2019.04.015

T. M. Ghazal, S. Abbas, S. Munir, M. A. Khan, M. Ahmad, G. F. Issa, S. B. Zahra, M. A. Khan, M. K. Hasan. Comput. Mater. Cont. 2022, 70(3), 5005. https://doi.org/10.32604/cmc.2022.020866

G. F. Makhaeva, S. V. Lushchekina, N. V. Kovaleva, T. Yu. Astakhova, N. P. Boltneva, E. V. Rudakova, O. G. Serebryakova, A. N. Proshin, I. V. Serkov, T. P. Trofimova, V. A. Tafeenko, E. V. Radchenko, V. A. Palyulin, V. P. Fisenko, J. Korábečný, O. Soukup, R. J. Richardson, Bioorg. Chem. 2021, 112, 104974. https://doi.org/10.1016/j.bioorg.2021.104974

G. Marucci, M. Buccioni, D. D. Ben, C. Lambertucci, R. Volpini, F. Amenta, Neuropharmacology 2021, 190(108352), 108352. https://doi.org/10.1016/j.neuropharm.2020.108352

J. Korábečný, E. Nepovimová, T. Cikánková, K. Špilovská, L. Vašková, E. Mezeiová, K. Kuča, J. Hroudová, Neuroscience 2018, 370, 191. https://doi.org/10.1016/j.neuroscience.2017.06.034

S. Akocak, M. Boga, N. Lolak, M. Tuneg, R. K. K. Sanku, J. Turkish Chem. Soc. Sect. A Chem. 2019, 6(1), 63. https://doi.org/10.18596/jotcsa.516444

A. Nordberg, C. Ballard, R. Bullock, T. Darreh‐Shori, M. Somogyi, Prim. Care Companion CNS Disord. 2013, 15(2). https://doi.org/10.4088/PCC.12r01412

European Pharmacopoeia 11th Edition, Strasbourg, France: European Directorate for the Quality of Medicines & Healthcare, 2022.

J. Muselík, A. Komersová, V. Lochař, K. Kubová, In: Chemické listy, Česká společnost chemická, Praha 2019, 113(5), pp. 328

J. Muselík, A. Komersová, K. Kubová, K. Matzick, B. Skalická, Pharmaceutics 2021, 13(10), 1703. https://doi.org/10.3390/pharmaceutics13101703

P. J. Das, B. Sarmah, Asian J. Chem. 2015, 27(1), 189. https://doi.org/10.14233/ajchem.2015.16853

Z. Šimková, Bc. SYNTÉZA BIOLOGICKY AKTIVNÍCH SULFONAMIDOVÝCH DERIVÁTŮ (MORFOLIN‐4‐YLMETHYL)ANILINU. Pardubice, 2020. Diplomová práce. Univerzita Pardubice, Fakulta chemicko‐technologická. Vedoucí práce Doc. Ing. Vladimír Pejchal, Ph.D. https://hdl.handle.net/10195/76203

G. Šinko, M. Čalić, A. Bosak, Z. Kovarik, Anal. Biochem. 2007, 370(2), 223. https://doi.org/10.1016/j.ab.2007.07.023

DrugBank. The Canadian Institutes of Health Research: Educe Design & Innovation Inc. (online), 2006. (cit. April 14, 2022) https://go.drugbank.com/

D. Voet, J. G. Voet. Biochemie. Praha: Victoria Publishing, 2005. ISBN 80‐856‐0544‐9.

B. Brus, U. Košak, S. Turk, A. Pišlar, N. Coquelle, J. Kos, J. Stojan, J. P. Colletier, S. Gobec, J. Med. Chem. 2014, 57(19), 8167. https://doi.org/10.1021/jm501195e

H. Ogura, T. Kosasa, Y. Kuriya, Y. Yamanishi, Methods Find. Exp. Clin. Pharmacol. 2000, 22(8), 609. https://doi.org/10.1358/mf.2000.22.8.701373

J. Wu, M. Pistolozzi, S. Liu, W. Tan, Bioorg. Med. Chem. 2020, 28(5), 115324. https://doi.org/10.1016/j.bmc.2020.115324